NextGen 16% Subcutaneous Immunoglobulin

· CSL Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NextGen 16% Subcutaneous Immunoglobulin, covering 2013-06-19 to 2013-06-19. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency [Phase 3]